Business Wire

Globalinternet: “Now is the Time to Rethink Your Sourcing Strategy for Network Connectivity”

5.10.2020 15:00:00 EEST | Business Wire | Press release

Share

Globalinternet, the Amsterdam-headquartered company that provides connectivity for more than 600 enterprises globally, today releases a white paper on what they call the ‘Accelerated Internet Shift’. The white paper focuses on the accelerating shift from private to public networks, including the impact of COVID-19 on large corporations that had to rethink their entire operational practices while employees were forced to work from home.

The white paper, commissioned in partnership with research consultancy Omdia, is a comprehensive tool for CIOs and IT executives around the world to get the latest insights regarding internet connectivity during the current pandemic and beyond. It underlines the importance for enterprises to prioritise network transformation projects and so becoming resilient in a post-COVID / Work-from-home world.

The research shows that existing global network service providers are a known quantity but more and more enterprises are looking for new suppliers to source their network services as a way to get fresh perspectives and more competitive solutions. For example: no less than 49% of enterprises turned to new network providers when adopting SD-WAN, and more than one-third of large enterprises expect to re-reconsider their primary network partner.

“The shift from private to public networks was a trend that was on our radar for a long time,” says Kees Bos, CEO Globalinternet. “But the big news is that this is accelerating at a high speed. Enterprises have felt the first shock from COVID and, despite needing to cut budgets for the foreseeable future, these enterprises are prioritizing the shift to internet and SD-WAN. They realize that money spent today on these network enhancements will help the company be nimbler and in a stronger position tomorrow”

The full white paper can be downloaded here.

About Globalinternet

Globalinternet is a leading provider for business-grade internet connectivity – anywhere on the planet. We partner with brilliant local Internet Service Providers and technology partners in 190+ countries to offer a best-in-class product portfolio with an unparalleled range of dedicated, broadband and mobile internet access services, coupled with around-the-clock assurance and support.

Founded in 2012, Globalinternet has worked since with more than 600 enterprises, delivering the underlay to enable their network transformation projects. Customers can monitor and manage their diverse internet services through the GINius customer portal. The portal supports APIs for fully automated integration with enterprises’ internal systems allowing them to take control of their internet underlay. For more information: www.globalinter.net

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contacts
Daniela Muente
Head of Global Marketing
Daniela.Muente@Globalinter.net
+31 654355430

Linda Roemer
Marketing Manager
Linda.Roemer@Globalinter.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release

Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye